[Federal Register Volume 68, Number 68 (Wednesday, April 9, 2003)]
[Notices]
[Page 17403]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-8585]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substances in Schedule I or II and prior to issuing a 
registration under section 1002(a) authorizing the importation of such 
a substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Sec.  1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on February 14, 
2003, Boehringer Ingelheim Chemicals, Inc. 2820 N. Normandy Drive, 
Petersburg, Virginia 23805, made application by renewal to the Drug 
Enforcement Administration to be registered as an importer of 
Phenylacetone (8501), a basic class of controlled substance listed in 
Schedule II.
    The firm plans to import Phenylacetone for the bulk manufacture of 
amphetamine.
    Any manufacturer holding, or apply for, registration as a bulk 
manufacturer of this basic class of controlled substance may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: Drug 
Operations Section, Domestic Drug Unit (ODOD), and must be filed no 
later than May 9, 2003.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), (f). As noted as a previous notice at 40 FR 43745-46 (Sepember 23, 
1975), all applicants for registration to import basic class of any 
controlled substance in Schedule I or II are and will continue to be 
required to demonstrate to the Deputy Assistant Administrator, Office 
of Diversion Control, Drug Enforcement Administration that the 
requirements for such registration pursuant to 21 U.S.C. 958(a), 21 
U.S.C. 823(a), and 21 CFR 1311.452(a), (b), (c), (d), (e), and (f) are 
satisfied.

    Dated: March 21, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-8585 Filed 4-8-03; 8:45 am]
BILLING CODE 4410-09-M